A Rapid Growth-Independent Antibiotic Resistance Detection Test by SYBR Green/Propidium Iodide Viability Assay

被引:30
作者
Feng, Jie [1 ]
Yee, Rebecca [1 ]
Zhang, Shuo [1 ]
Tian, Lili [2 ]
Shi, Wanliang [1 ]
Zhang, Wen-Hong [3 ]
Zhang, Ying [1 ]
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21218 USA
[2] Beijing Res Inst TB Control, Beijing, Peoples R China
[3] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Key Lab Med Mol Virol,Dept Infect Dis, Shanghai, Peoples R China
关键词
antibiotic resistance; antimicrobial susceptibility testing; SYBR Green/PI availability assay; Mycobacterium tuberculosis; Staphylococcus sureus; CRE bacteria; MYCOBACTERIUM-TUBERCULOSIS; SUSCEPTIBILITY; PYRAZINAMIDE; SURVEILLANCE; INDICATOR;
D O I
10.3389/fmed.2018.00127
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antibiotic-resistant bacteria have caused huge concerns and demand innovative approaches for their prompt detection. Current antimicrobial susceptibility tests (AST) rely on the growth of the organisms which takes 1-2 days for fast-growing organisms and several weeks for slow growing organisms. Here, we show for the first time the utility of the SYBR Green I/propidium iodide (PI) viability assay for rapidly identifying antibiotic resistance in less than 30 min for major, antibiotic-resistant, fast-growing bacteria, such as Staphylococcus aureus, Escherichia coil, Klebsiella pneumoniae, and Acinetobacter baumannii for bactericidal and bacteriostatic agents and in 16 h for extremely rapid detection of drug resistance for isoniazid and pyrazinamide in slow-growing Mycobacterium tuberculosis. The SYBR Green I/PI assay generated rapid and robust results in concordance with traditional AST methods. This novel growth-independent methodology changes the concept of the current growth-based AST and may revolutionize current drug susceptibility testing for all cells of prokaryotic and eukaryotic origin and, subject to further clinical validation, may play a major role in saving lives and improving patient outcomes.
引用
收藏
页数:11
相关论文
共 33 条
[1]   Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide [J].
Aragon, Lina Marcela ;
Garrigo, Montserrat ;
Moreno, Carmen ;
Espanol, Montserrat ;
Coll, Pere .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (03) :655-657
[2]  
Barbesti S, 2000, CYTOMETRY, V40, P214, DOI 10.1002/1097-0320(20000701)40:3<214::AID-CYTO6>3.3.CO
[3]  
2-D
[4]   Antibacterial drug discovery in the resistance era [J].
Brown, Eric D. ;
Wright, Gerard D. .
NATURE, 2016, 529 (7586) :336-343
[5]   Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Combined Species Identification and Drug Sensitivity Testing in Mycobacteria [J].
Ceyssens, Pieter-Jan ;
Soetaert, Karine ;
Timke, Markus ;
Van den Bossche, An ;
Sparbier, Katrin ;
De Cremer, Koen ;
Kostrzewa, Markus ;
Hendrickx, Marijke ;
Mathys, Vanessa .
JOURNAL OF CLINICAL MICROBIOLOGY, 2017, 55 (02) :624-634
[6]   Potential for Erroneous Results Indicating Resistance When Using the Bactec MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide [J].
Chedore, Pamela ;
Bertucci, Lina ;
Wolfe, Joyce ;
Sharma, Meenu ;
Jamieson, Frances .
JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (01) :300-301
[7]  
CLSI, 2016, M100S CLSI NCCLS
[8]  
CLSI, 2011, M24A2 CLSI NCCLS
[9]   Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance [J].
Davies, Sally C. ;
Fowler, Tom ;
Watson, John ;
Livermore, David M. ;
Walker, David .
LANCET, 2013, 381 (9878) :1606-1609
[10]   An Optimized SYBR Green I/PI Assay for Rapid Viability Assessment and Antibiotic Susceptibility Testing for Borrelia burgdorferi [J].
Feng, Jie ;
Wang, Ting ;
Zhang, Shuo ;
Shi, Wanliang ;
Zhang, Ying .
PLOS ONE, 2014, 9 (11)